That's not to say it might not be worth it for someone with COPD, lung disease or serious immunocompromise or something, but you seem to be lacking a pragmatic understanding of the situation described, yet you're readily criticizing me on the basis of an (incorrect) ad hominem argument.
Tamiflu is a much better example than Nyquil (which you offered up earlier) where it does make sense. But in that case, influenza typically lasts longer, it's more serious, it's much easier to diagnose, and the potential complications are much more severe and likely. It's probably more prevalent as well.
You seem to be coming at things in terms of patient trade-offs. I’m saying that AbbVie loves selling more Humira, and some sort of hypothetical magical anti-infective would’ve been a way to do so.